Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FATE THERAPEUTICS INCFATE · Entity 5968 | See Remarks | January 15, 2025 | January 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FATE THERAPEUTICS INC
Report date January 15, 2025 · Filed January 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 335,203 |
Reported balance
After 2025-01-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-01-15 · Grant · Acquired 65,000 · Balance 335,203 F1: Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of January 8, 2026, January 8, 2027, January 8, 2028 and January 8, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2035-01-14 | Direct | 250,000 |
Reported balance
After 2025-01-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-01-15 · Grant · Acquired 250,000 · Balance 250,000 F2: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2025, such that all of the shares shall be fully vested and exercisable on January 1, 2028, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of January 8, 2026, January 8, 2027, January 8, 2028 and January 8, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.
F2: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2025, such that all of the shares shall be fully vested and exercisable on January 1, 2028, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2025 Filed Jan 16, 2025 18:31 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0000950170-25-006310 · ownership.xml · derivative · entry 2 Bressi Jerome Charles · CIK 0002034505 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2035-01-14 F2 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2025, such that all of the shares shall be fully vested and exercisable on January 1, 2028, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Read SEC document |
| January 15, 2025 Filed Jan 16, 2025 18:31 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-006310 · ownership.xml · nonDerivative · entry 1 Bressi Jerome Charles · CIK 0002034505 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,203 F1 · security: Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of January 8, 2026, January 8, 2027, January 8, 2028 and January 8, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 16:06 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 5,980 | $1.55 | $9,269.00 |
DisclosureSEC source: 0000950170-25-004825 · ownership.xml · nonDerivative · entry 1 Bressi Jerome Charles · CIK 0002034505 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,203 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 2,188 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021 and 6,660 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $1.51 to $1.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.